Glucagon Like Peptide-۱: A Novel Therapeutic Strategy in Non-alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is a main cause of liver disease and its global prevalence is estimated to be ۲۴%. At present no approved medicines are available for NAFLD treatment. Glucagon-like peptide-۱ (GLP-۱) is a significant regulator of energy balance, show potential efficacy in the management of NAFLD. GLP-۱ and GLP-۱ receptor agonist (GLP-۱RAs) are attractive options for the treatment of type ۲ diabetes (T۲D) since they efficiently reduce weight, HbA۱C and blood glucose without having a risk of hypoglycaemia. This incretin hormone by normalizing of insulin resistance (IR), oxidative stress, lipid accumulation, lipotoxicity, and liver cell apoptosis is proposed for the management of NAFLD and nonalcoholic steatohepatitis (NASH) patient. Hence, the aim of this review was to discuss the useful effects of GLP-۱, GLP-۱ receptor agonist (GLP-۱RAs) and dipeptidyl peptidase-۴ (DPP-۴) on NAFLD. In this paper we provided a new finding which highlighted the role of GLP-۱ and GLP-۱RAs in the treatment of NAFLD.